mRNA Therapeutics in Non-small Cell Lung Cancer (NSCLC)

The treatment of non-small cell lung cancer had remained the top cause of death globally, is one important area in oncology where messenger RNA therapy has shown promise. In contrast with traditional treatments, mRNA therapeutics offer quick development times and the ability to trigger immune responses without integrating into the host cell. mRNA therapeutics relies on the delivery of mRNA molecules into host cells then the intracellular production of these proteins subsequently activates adaptive immune responses, enabling targeted recognition and elimination of cancer cells. However, most of existing versions show tropism toward the liver, which reduces their effectiveness in targeting lung tissue, making delivery remains a major obstacle. To increase tissue preference and therapeutic accuracy, local delivery options are being actively investigated. Attention must also be taken to safety factors including the potential for unexpected protein translation including outcomes from repeated doses. Widespread clinical use is further hampered by cold-chain coordination, large-scale production, and strict regulatory requirements, especially in areas with limited resources. Personalized mRNA cancer vaccines are designed to eliminate immune responses against neoantigens that are specific to an individuals tumor. Self-amplifying RNA (saRNA), also known as self-replicating RNA (srRNA), represent a modified mRNA molecule that can replicate itself within host cells, enhancing protein expression and boosting the immune response. In addition, its extended and enhanced expression in vivo enables effective vaccination even at low doses.